Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895".
Daniel RaysonSonal GandhiAnil A JoyChristine Brezden-MasleyKaren A GelmonSandeep SehdevDavid CesconStephen ChiaPublished in: Current oncology (Toronto, Ont.) (2023)
We appreciate the opportunity to respond to the comment [...].